IgM myeloma: A multicenter retrospective study of 134 patients. Issue 8 (26th May 2017)

• Record Type: Journal Article
• Authors: Castillo, Jorge J.; Jurczyszyn, Artur; Brozova, Lucie; Crusoe, Edvan; Czepiel, Jacek; Davila, Julio; Dispenzieri, Angela; Eveillard, Marion; Fiala, Mark A.; Ghobrial, Irene M.; Gozzetti, Alessandro; Gustine, Joshua N.; Hajek, Roman; Hungria, Vania; Jarkovsky, Jiri; Jayabalan, David; Laubach, Jacob P.; Lewicka, Barbara; Maisnar, Vladimir; Manasanch, Elisabet E.; Moreau, Philippe; Morgan, Elizabeth A.; Nahi, Hareth; Niesvizky, Ruben; Paba‐Prada, Claudia; Pika, Tomas; Pour, Ludek; Reagan, John L.; Richardson, Paul G.; Shah, Jatin; Spicka, Ivan; Vij, Ravi; Waszczuk‐Gajda, Anna; Gertz, Morie A.;
• Is Part Of: American journal of hematology. Volume 92:Issue 8(2017:Aug.)
• Page Start: 746
• Page End: 751
• Publication Date: 2017-05-26
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24753
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2, 895 mg dL −1 with 19% of patients presenting with levels >6, 000 mg dL −1 . International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t (11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival ( P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.